Option chain shows key data for Brookfield Prop Partners's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Brookfield Prop Partners.

Brookfield Prop Partners (NASDAQ:BPYPP) Stock, Option Chain

Brookfield Prop Partners

Brookfield Property Partners LP owns, operates, and invests in commercial properties in North America, Europe, Australia, and Brazil. The company focuses on being an owner and operator of real estate, providing investors with diversified exposure to some of the iconic properties and acquiring high-quality assets at a discount to replacement cost or intrinsic value. Its operating segment includes Core Office, Core Retail, LP Investments, and Corporate Segments. The company operates in various sectors such as the office sector, retail sector, industrial, multifamily, hospitality, triple net lease, and corporate sector. It generates a majority of revenue from the LP Investments segment.

News

Intraday Update

Markets

Movers

Trading Ideas

ALLE

AMKR

AMRR

ATBPF

ATEC

BDSI

BEVVF

BPYPP

BUKS

CODI

CROX

CWTC

CXKJ

DOOR

EPIX

FITBO

FLOW

FMBV

GNBT

GPIW

GRMN

HURN

IMXI

IPHI

ISEE

KBLM

KFRC

MFSF

MGRC

NBTB

NSIT

NUAN

PDFS

PRFT

PSMT

QALB

QCRH

RDCM

REPH

RETA

REXR

RLBY

RPAI

SHOO

SITC

SITE

SLGX

TMEB

TRNS

TRRSF

VNWTF

VRTX

WTBA

SLFYF

ELEEF

CMCL

FBAYF

IMMB

Stocks That Hit 52-Week Highs On Wednesday

Movers & Shakers

General

AAPL

APLT

ATKR

BVFL

CELP

CMRE

CNST

COWPP

EBSB

FABK

FDEF

GNRC

GOLF

GOODN

HMCBF

HNGR

IMUC

IRET

KBAL

LTXB

MLRKF

MSEX

NDSN

PBBI

PDIV

PPBI

QSMG

ROIC

RQHTF

SALT

SIMA

SMED

SMTI

SPAR

STRL

TRCB

UCBI

UCFC

VICI

ATZAF

SCTSF

ALLIF

EZEN

ARWR

BLDR

BMCH

CASH

CELG

CGEAF

CHCT

COLD

DCOM

DLTR

DMKBB

EMBR

ENTG

ESGRO

ETBI

FBHS

FFIN

GNTX

IESC

INFO

KRNT

LULU

LYTS

MGDPF

MNRLF

MRTN

NCEN

NFBK

NGUGF

NXRT

OCSM

ODFL

PFSI

PLMR

PLUG

ROST

SAIA

SBAZ

SBRA

SCND

SGEN

SNNAF

SNWR

TFSL

TMHC

WERN

WODI

ZAYO

GWLOF

DUNDF

MRCBF

PGVI

ACCR

Stocks That Hit 52-Week Highs On Friday

Brookfield Property Partners L.P. - 6.50% Class A Cumulative Redeemable Perpetual Preferred Units

Brookfield Property Partners LP

German sportswear brand Adidas AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ADDYY#OTC">ADDYY</a>) has released its <a target="_blank" href="https://www.adidas-group.com/en/media/press-releases/adidas-finishes-successful-year-with-better-than-expected-fourth-quarter-results" rel="noreferrer noopener">preliminary </a>results for the fourth quarter of 2024.
The company&#8217;s revenue increased by 19% in currency-neutral terms, with a 24% rise in euro terms, totaling 5.97 billion euros (~$6.24 billion). Excluding <a target="_blank" href="https://www.benzinga.com/news/earnings/24/04/38511886/adidas-puts-yeezy-history-behind-rides-fashion-high-with-samba-and-gazelle-shoes" rel="noreferrer noopener">Yeezy sales from both years</a>, currency-neutral growth was 18%.
Additionally, the company saw a notable improvement in its gross margin, which grew by 520 basis points to 49.8%, up from 44.6% in 2023.
Fourth-quarter operating profit reached 57 million euros, reversing the 377 million euros loss recorded in the same quarter last year.
Adidas also posted strong growth for the full year 2024. Its revenue climbed 12% on a currency-neutral basis, reaching 23.68 billion euros. When excluding Yeezy sales, the company saw a 13% increase in currency-neutral revenues.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/01/43098100/costco-workers-vote-to-strike-over-fair-contract-demands" rel="noreferrer noopener">Costco Workers Vote To Strike Over Fair Contract Demands</a>
The gross margin for the year improved by 330 basis points, reaching 50.8%. Operating profit surged by over 1 billion euros, rising from 268 million euros in 2023 to 1.34 billion euros in 2024.
&#8220;We clearly see that consumers&#8217; and retailers&#8217; interest in our products is growing across both Lifestyle and Performance. Strong growth across all regions and divisions proves the good job our teams are doing across regions and functions,&#8221; said CEO Bjørn Gulden.
&#8220;We also feel good about the future, and we see potential to increase our market share in all markets. There is a lot of macroeconomic uncertainty right now, but we clearly have the goal to again grow double-digit with the adidas brand and use that growth to continue to improve our operating profit and make further progress towards our 10% margin target.&#8221;
Price Action: ADDYY shares closed higher by 6.59% at $132.22 on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43108106/volkswagen-warns-of-tariffs-impact-on-us-consumers" target="_blank" rel="noreferrer noopener">Volkswagen &#8216;Concerned&#8217; Over Trump Tariffs: Will Automakers Pass Costs To US Consumers?</a></li>
</ul>
Image via Shutterstock.

Equities

Guidance

ADDYY

Adidas Sees Solid Gains In Q4, Looks To Expand Market Share

Barclays analyst Simon Coles downgrades STMicroelectronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) from Equal-Weight to Underweight.

Downgrades

Analyst Ratings

Barclays Downgrades STMicroelectronics to Underweight

JP Morgan analyst Mark Murphy downgrades Paycor HCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYCR#NASDAQ">PYCR</a>) from Neutral to Underweight and raises the price target from $21 to $22.5.

Price Target

PYCR

JP Morgan Downgrades Paycor HCM to Underweight, Raises Price Target to $22.5

JP Morgan analyst James Kirby initiates coverage on Sun Country Airlines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCY#NASDAQ">SNCY</a>) with a Overweight rating and announces Price Target of $23.

Initiation

SNCY

JP Morgan Initiates Coverage On Sun Country Airlines with Overweight Rating, Announces Price Target of $23

JP Morgan analyst DS Kim downgrades New Oriental Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) from Overweight to Neutral and lowers the price target from $85 to $50.

New Oriental Education & Technology Group

JP Morgan Downgrades New Oriental Education to Neutral, Lowers Price Target to $50

Tesla Inc. CEO Elon Musk cast doubt Wednesday on the ambitious $500 billion Project Stargate, hours after its announcement, claiming lead investor SoftBank Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>) has &#8220;well under $10B secured.&#8221;
What Happened: The project, unveiled Tuesday at a White House briefing in the presence of President Donald Trump, represents a joint venture between OpenAI, SoftBank, and Oracle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) to establish massive <a href="https://www.benzinga.com/25/01/43111153/nvidia-and-ai-stock-rises-as-trump-announces-500-billion-stargate-ai-infrastructure-venture">artificial intelligence infrastructure across the United States</a>. 
&#8220;They don't actually have the money,&#8221; Musk said.
&#8220;SoftBank has well under $10B secured. I have that on good authority.&#8221;
During the briefing, Oracle co-founder Larry Ellison highlighted the project&#8217;s healthcare applications, including an AI-driven system capable of delivering personalized cancer vaccines within 48 hours. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">SoftBank has well under $10B secured. I have that on good authority.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1881944244480565497?ref_src=twsrc%5Etfw">January 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/general/biotech/25/01/43119814/google-parent-owned-startup-to-launch-ai-designed-drug-trials-by-year-end-partnering-with-eli-lilly-and-novartis-to-tackle-major-diseases">Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases</a>
Why It Matters: The initiative plans to deploy an initial $100 billion immediately, starting with a 500,000-square-foot data center in Abilene, Texas. Nine additional facilities are planned, with potential expansion to 20 locations.
Technology partners Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), and Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) saw their stocks climb on the news. NVIDIA rose 3.95% to $143.15, while Arm jumped 8.94% to $162.60.
OpenAI, maintaining operational responsibility while SoftBank leads financial aspects, stated the project &#8220;will secure American leadership in AI&#8221; and &#8220;create hundreds of thousands of American jobs.&#8221; SoftBank&#8217;s Masayoshi Son will serve as chairman.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/43119464/netflix-raises-prices-16-peter-schiff-warns-of-escalating-inflation-risks-ahead-of-trump-policies">Netflix Raises Prices 16%, Peter Schiff Warns Of Escalating Inflation Risks Ahead Of Trump Policies</a></li>
</ul>
Image via Wikimedia Commons
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

MSFT

NVDA

ORCL

SFTBF

SFTBY

Elon Musk Says Project Stargate Doesn't 'Actually Have The Money' After Trump Announces $500 Billion AI Investment Led By SoftBank, Oracle And OpenAI

Jefferies analyst Dennis Ding upgrades Crinetics Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNX#NASDAQ">CRNX</a>) from Hold to Buy and announces $55 price target.

Upgrades

CRNX

Jefferies Upgrades Crinetics Pharmaceuticals to Buy, Announces $55 Price Target

Comments

Brookfield Prop Partners

Brookfield Prop Partners (BPYPP) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga